"Today's news marks a substantial advancement in neuroscience. This is long-awaited progress in finding a treatment for Alzheimer's disease," said IREM Professor and Neurimmune’s CEO Roger Nitsch. "For decades, patients, families and caregivers have been hoping for a scientific breakthrough leading to clinical benefit."
For the first time, large late-stage clinical study results showed that removal of amyloid in the brain can translate into clinically meaningful effects on both cognition and function in patients with Alzheimer's disease. Aducanumab - the antibody mediating amyloid removal - was among the first human antibodies Neurimmune developed through its Reverse Translational Medicine platform. This technology translates antibody-encoding genetic information obtained from human white blood cells into therapeutic antibodies.
"This continues to be a fascinating journey, from a small team of passionate scientists experimenting in the university lab, to prototyping by a startup biotech company, to creating a world-wide multidisciplinary collaboration of thousands of dedicated researchers, antibody manufacturing experts, clinical investigators and study nurses," said Roger Nitsch. "Today, we are moving a meaningful step closer toward our joint goal of delivering a treatment for Alzheimer's disease."
IREM continues to develop translational approaches to move scientific discoveries towards innovative biomedical products designed to improve medical care. With it's teaching program in Bio-Entrepreneurship, IREM is training students and junior scientists to create successful startups for the development of their innovations.
Link to Neurimmune Media Release: http://www.neurimmune.com/newsarticle/22102019-neurimmune-welcomes-biogens-news-on-clinical-benefit-of-aducanumab.html
Link to Biogen’s presentation on October 22, 2019: http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c
Link to BioEntrepreneurship & Innovation Program at IREM https://www.irem.uzh.ch/en/teaching/bioentrepreneurship.html